THC:CBD Farmacêutico

termo de indexação original: Pharma THC:CBD

O que é THC:CBD Farmacêutico

THC:CBD Farmacêutico reúne os estudos com preparações que combinam os dois canabinoides em proporção definida — tipicamente 1:1 — em vez de um deles isolado.

A formulação mais estudada é um spray oromucoso derivado de extrato vegetal padronizado, aprovado em vários países para espasticidade associada à esclerose múltipla. Por ser extrato padronizado e não moléculas sintéticas, ocupa um lugar intermediário entre o medicamento de molécula única e o produto de planta.

O interesse na combinação vem da hipótese de que o CBD atenua alguns efeitos do THC, ampliando a janela de dose tolerada. Essa hipótese é testada com frequência nos estudos desta página — e nem sempre confirmada.

No acervo

O acervo do Cannabis Indica reúne 248 estudos científicos que tocam o composto THC:CBD Farmacêutico, publicados entre 2003 e 2024. Pela leitura automatizada, 199 (80%) foram classificados como favoráveis, 29 (12%) como inconclusivos e 20 (8%) como desfavoráveis — uma leitura de máquina, feita para navegar, não para concluir. O desenho mais frequente é metanálise (109 estudos), seguido de ensaio clínico (46). As condições mais associadas são Esclerose Múltipla, Dor e Dor — Crônica.

Estudos indexados: 248
Período coberto: 2003–2024
Favoráveis: 199 · 80%
Inconclusivos: 29 · 12%
Desfavoráveis: 20 · 8%
Termo original: Pharma THC:CBD

O acervo em números

Tipo de estudo

Metanálise109

Ensaio Clínico46

Ensaio Clínico Duplo-Cego42

Metanálise Clínica37

Estudo em Animais11

Estudo Laboratorial3

Direção do resultado

Favorável199

Inconclusivo29

Desfavorável20

Por década

2000s16

2010s112

2020s120

Aparece junto com

Esclerose Múltipla94 Dor89 Dor — Crônica49 Câncer34 Dor — Neuropatia Periférica29 Epilepsia28 Dependência — Cannabis27 Ansiedade27

248 estudos

Filtrar e buscar no acervo →

2024
Application of the Bayesian network theory in clinical trial data: Severity shift in spasticity numeric rating scale in patients with multiple sclerosis
FavorávelMetanálise ClínicaEsclerose Múltipla
2024
Assessment of Clinical Outcomes in Patients With Osteoarthritis: Analysis From the UK Medical Cannabis Registry
FavorávelMetanáliseDor Ansiedade Insônia e Distúrbios do Sono THC Farmacêutico CBD Farmacêutico+1
2024
The Effect of Nabiximols on Driving Ability in Adults with Chronic Tic Disorders: Results of a Substudy Analysis of the Double-Blind, Randomized, Placebo-Controlled CANNA-TICS Trial
FavorávelEnsaio Clínico Duplo-CegoEfeitos Adversos da Cannabis Disfunção Cognitiva Tiques e Síndrome de Tourette
2023
CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders - Results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study
FavorávelEnsaio Clínico Duplo-CegoDepressão TDA e TDAH Tiques e Síndrome de Tourette+1
2023
Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm - A Randomized Pilot Study
FavorávelEnsaio Clínico Duplo-CegoDor Câncer Dor — Crônica THC Farmacêutico CBD Farmacêutico+8
2023
Cannabidiol safety considerations: Development of a potential acceptable daily intake value and recommended upper intake limits for dietary supplement use
FavorávelEnsaio ClínicoDor Câncer Efeitos Adversos da Cannabis Tetraidrocanabinol (THC)CBD Farmacêutico+10
2023
Cannabis-opioid interaction in the treatment of fibromyalgia pain: an open-label, proof of concept study with randomization between treatment groups: cannabis, oxycodone or cannabis/oxycodone combination-the SPIRAL study
InconclusivoMetanáliseDependência Química Dor — Crônica Dependência — Opioides THC Farmacêutico CBD Farmacêutico+1
2023
Climbing the Evidence Pyramid: Dosing Considerations for Medical Cannabis in the Management of Chronic Pain
FavorávelMetanáliseDor Dor — Crônica Tetraidrocanabinol (THC)THC Farmacêutico+1
2023
Clinical Research Evidence Supporting Administration and Dosing Recommendations of Medicinal Cannabis as Analgesic in Cancer Patients
FavorávelMetanálise ClínicaDor Dor — Oncológica
2023
Could cannabinoids provide a new hope for ovarian cancer patients?
FavorávelMetanáliseDor Câncer Inflamação Anandamida (AEA)2-Araquidonoilglicerol (2-AG)+24
2023
Effects of Chronic, Low-Dose Cannabinoids, Cannabidiol, Delta-9-Tetrahydrocannabinol and a Combination of Both, on Amyloid Pathology in the 5xFAD Mouse Model of Alzheimer's Disease
InconclusivoEstudo em AnimaisDoença de Alzheimer THC Farmacêutico CBD Farmacêutico
2023
Effects of sub-chronic nabiximols on biological markers of individuals undergoing a clinical trial for the treatment of cannabis use disorder
FavorávelMetanáliseDependência Química Dependência — Cannabis
2023
Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials
FavorávelMetanálise ClínicaEsclerose Múltipla
2023
Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review
InconclusivoMetanáliseDor Câncer Inflamação Anandamida (AEA)Endocanabinoide (não especificado)+26
2023
Nabiximols is Efficient as Add-On Treatment for Patients with Multiple Sclerosis Spasticity Refractory to Standard Treatment: A Systematic Review and Meta-Analysis of Randomised Clinical Trials
FavorávelMetanáliseEsclerose Múltipla
2023
Phytocannabinoids: Pharmacological effects, biomedical applications, and worldwide prospection
InconclusivoMetanálise ClínicaDor Câncer Ansiedade THC Farmacêutico Canabigerol (CBG)+9
2023
The effect of tetrahydrocannabinol:cannabidiol oromucosal spray on cognition: a systematic review
InconclusivoMetanáliseEfeitos Adversos da Cannabis Disfunção Cognitiva
2023
Use of Cannabidiol in the Management of Insomnia: A Systematic Review
FavorávelMetanálise ClínicaInsônia e Distúrbios do Sono Tetraidrocanabinol (THC)
2022
A Randomized, Triple-Blind, Comparator-Controlled Parallel Study Investigating the Pharmacokinetics of Cannabidiol and Tetrahydrocannabinol in a Novel Delivery System, Solutech, in Association with Cannabis Use History
FavorávelEnsaio ClínicoEfeitos Adversos da Cannabis
2022
A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis
DesfavorávelMetanálise ClínicaEsclerose Múltipla
2022
Botanically-Derived Δ 9-Tetrahydrocannabinol and Cannabidiol, and Their 1:1 Combination, Modulate Toll-like Receptor 3 and 4 Signalling in Immune Cells from People with Multiple Sclerosis
FavorávelEstudo LaboratorialEsclerose Múltipla
2022
Cannabinoid Effect and Safety in Spasticity Following Stroke: A Double-Blind Randomized Placebo-Controlled Study
InconclusivoEnsaio Clínico Duplo-CegoAVC Tetraidrocanabinol (THC)
2022
Cannabinoids in rheumatology: Friend, foe or a bystander?
InconclusivoMetanáliseDor Dor — Crônica Epilepsia Anandamida (AEA)Tetraidrocanabinol (THC)+19
2022
Cannabinoids in the Treatment of Cannabis Use Disorder: Systematic Review of Randomized Controlled Trials
FavorávelMetanálise ClínicaDependência Química Dependência — Cannabis Hidrolase de Amidas de Ácidos Graxos (FAAH)THC Farmacêutico
2022
Cannabinoids reduce opioid use in older patients with pain : Retrospective three-year analysis of data from a general practice
FavorávelMetanáliseDor Dor — Crônica THC Farmacêutico
2022
Cannabinoids to Improve Health-Related Quality of Life in Patients with Neurological or Oncological Disease: A Meta-Analysis
InconclusivoMetanálise ClínicaCâncer Ansiedade Depressão Canabinoide Sintético (não especificado)THC Farmacêutico+5
2022
Cannabinoids: Therapeutic Use in Clinical Practice
FavorávelMetanálise ClínicaCâncer Epilepsia Doenças Neurodegenerativas Anandamida (AEA)Tetraidrocanabinol (THC)+16
2022
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis
InconclusivoMetanálise ClínicaDor Dor — Crônica Psicose THC Farmacêutico CBD Farmacêutico+1
2022
Cannabis in Parkinson's Disease - the patient's perspective versus clinical trials: a systematic literature review
DesfavorávelMetanálise ClínicaDor Inflamação Ansiedade Anandamida (AEA)Endocanabinoide (não especificado)+5
2022
Cannabis-Based Products for Chronic Pain : A Systematic Review
FavorávelMetanálise ClínicaDor Inflamação Dependência — Cannabis Tetraidrocanabinol (THC)THC Farmacêutico+7
2022
Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review
FavorávelMetanáliseDor Câncer Inflamação Anandamida (AEA)Tetraidrocanabinol (THC)+28
2022
Change in upper limb function in people with multiple sclerosis treated with nabiximols: a quantitative kinematic pilot study
FavorávelEnsaio ClínicoInflamação Disfunção Cognitiva Doenças Neurodegenerativas+1
2022
Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: an open label study
FavorávelEnsaio ClínicoAnsiedade Insônia e Distúrbios do Sono Transtornos de Comportamento Anandamida (AEA)Tetraidrocanabinol (THC)+3
2022
Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia
DesfavorávelEnsaio ClínicoCâncer Câncer — Leucemia Câncer — Linfoma Tetraidrocanabinol (THC)
2022
Comparison of the Effectiveness and Tolerability of Nabiximols (THC:CBD) Oromucosal Spray versus Oral Dronabinol (THC) as Add-on Treatment for Severe Neuropathic Pain in Real-World Clinical Practice: Retrospective Analysis of the German Pain e-Registry
FavorávelMetanáliseDor Dor — Crônica THC Farmacêutico
2022
Controversial Link between Cannabis and Anticancer Treatments—Where Are We and Where Are We Going? A Systematic Review of the Literature
FavorávelMetanáliseDor Câncer Ansiedade Tetraidrocanabinol (THC)THC Farmacêutico+17
2022
Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder
FavorávelEnsaio Clínico Duplo-CegoDor Dependência Química Dependência — Cannabis Tetraidrocanabinol (THC)+4
2022
Cutaneous Squamous Cell Carcinoma and Lichen Simplex Chronicus Successfully Treated with Topical Cannabinoid Oil: A Case Report and Summary of Cannabinoids in Dermatology
FavorávelMetanáliseCâncer Inflamação Ansiedade Anandamida (AEA)Endocanabinoide (não especificado)+24
2022
Does Cannabidiol Have a Benefit as a Supportive Care Drug in Cancer?
FavorávelMetanáliseDor Câncer Efeitos Adversos da Cannabis Anandamida (AEA)Endocanabinoide (não especificado)+19
2022
Effects of SativexⓇ on cognitive function in patients with multiple sclerosis: A systematic review and meta-analysis
FavorávelMetanálise ClínicaDisfunção Cognitiva Esclerose Múltipla
2022
Efficiency of Inhaled Cannabidiol in Cannabis Use Disorder: The Pilot Study Cannavap
FavorávelMetanáliseDependência Química Câncer Inflamação THC Farmacêutico+12
2022
Endothelial dysfunction and angiogenesis: what is missing from COVID-19 and cannabidiol story?
FavorávelMetanáliseInflamação Epilepsia Esclerose Múltipla Tetraidrocanabinol (THC)Endocanabinoide (não especificado)+7
2022
Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap
FavorávelMetanálise ClínicaDor Dor — Crônica Disfunção Cognitiva Tetraidrocanabinol (THC)+2
2022
Impact of cannabinoids on pregnancy, reproductive health and offspring outcomes
DesfavorávelMetanáliseDor Dependência Química Câncer+15
2022
Intrathecal Actions of the Cannabis Constituents Δ(9)-Tetrahydrocannabinol and Cannabidiol in a Mouse Neuropathic Pain Model
FavorávelEstudo em AnimaisDor Dor — Crônica Dor — Neuropatia Periférica THC Farmacêutico Canabinoides Sintéticos AM-x
2022
Is There a Place for Medicinal Cannabis in Treating Patients with Sleep Disorders? What We Know so Far
FavorávelMetanálise ClínicaInsônia e Distúrbios do Sono Apneia do Sono Síndrome das Pernas Inquietas Tetraidrocanabinol (THC)THC Farmacêutico+3
2022
Long-term and serious harms of medical cannabis and cannabinoids for chronic pain: a systematic review of non-randomised studies
DesfavorávelMetanáliseDor Câncer Inflamação Anandamida (AEA)THC Farmacêutico+14
2022
Long-term observational studies with cannabis-based medicines for chronic non-cancer pain: A systematic review and meta-analysis of effectiveness and safety
FavorávelMetanáliseDor Ansiedade Dor — Crônica Hidrolase de Amidas de Ácidos Graxos (FAAH)THC Farmacêutico+5
2022
Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications
FavorávelMetanálise ClínicaDependência — Cannabis Ansiedade Depressão Tetraidrocanabinol (THC)THC Farmacêutico+17
2022
Medicinal Cannabis for the Treatment of Chronic Refractory Pain: An Investigation of the Adverse Event Profile and Health-Related Quality of Life Impact of an Oral Formulation
FavorávelEnsaio ClínicoDor Dor — Crônica
2022
Medicinal cannabis improves sleep in adults with insomnia: a randomised double-blind placebo-controlled crossover study
FavorávelEnsaio Clínico Duplo-CegoInsônia e Distúrbios do Sono Tetraidrocanabinol (THC)
2022
Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial
FavorávelEnsaio Clínico Duplo-CegoDor Dependência Química Efeitos Adversos da Cannabis Tetraidrocanabinol (THC)+3
2022
Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/consensus guidance on the use of cannabinoids for gastrointestinal symptoms in patients with cancer
InconclusivoMetanálise ClínicaCâncer Náusea e Vômito Anorexia (perda de apetite)THC Farmacêutico+3
2022
Nabiximols effect on blood pressure and heart rate in post-stroke patients of a randomized controlled study
InconclusivoEnsaio Clínico Duplo-CegoDoenças Cardiovasculares (DCV)AVC Hipertensão Arterial Tetraidrocanabinol (THC)+1
2022
Neurological Benefits, Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: A Systematic Review of Cannabinoid Effects in Multiple Sclerosis and Experimental Models of Demyelination
FavorávelMetanáliseEsclerose Múltipla Tetraidrocanabinol (THC)Canabinoides Sintéticos WIN-x
2022
Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies
FavorávelMetanáliseDependência Química Dependência — Opioides Anandamida (AEA)Endocanabinoide (não especificado)+9
2022
Placebo Response and Media Attention in Randomized Clinical Trials Assessing Cannabis-Based Therapies for Pain: A Systematic Review and Meta-analysis
InconclusivoMetanálise ClínicaDor Esclerose Múltipla Dor — Neuropatia Periférica Tetraidrocanabinol (THC)THC Farmacêutico
2022
Practical Considerations for the Use of Cannabis in Cancer Pain Management—What a Medical Oncologist Should Know
FavorávelMetanáliseDor Câncer Epilepsia Anandamida (AEA)2-Araquidonoilglicerol (2-AG)+14
2022
Randomised, pragmatic, waitlist controlled trial of cannabis added to prescription opioid support on opioid dose reduction and pain in adults with chronic non-cancer pain: study protocol
InconclusivoMetanáliseDor Dor — Crônica Dependência — Opioides THC Farmacêutico
2022
Role of cannabis in inflammatory bowel diseases
InconclusivoMetanáliseDor Inflamação Náusea e Vômito Anandamida (AEA)Endocanabinoide (não especificado)+14
2022
Safety and Tolerability of Oral Cannabinoids in People Living with HIV on Long-Term ART: A Randomized, Open-Label, Interventional Pilot Clinical Trial (CTNPT 028)
FavorávelEnsaio ClínicoInflamação HIV/AIDS Hepatite Tetraidrocanabinol (THC)CBD Farmacêutico
2022
Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Yellow Oil in Healthy Participants
FavorávelEnsaio ClínicoEfeitos Adversos da Cannabis Epilepsia — Síndrome de Dravet Epilepsia — Lennox-Gastaut Tetraidrocanabinol (THC)CBD Farmacêutico+2
2022
The C4EB study-Transvamix (10% THC / 5% CBD) to treat chronic pain in epidermolysis bullosa: A protocol for an explorative randomized, placebo controlled, and double blind intervention crossover study
InconclusivoMetanáliseDor Dor — Crônica Epidermólise Bolhosa
2022
The effect of medical cannabis on cognitive functions: a systematic review
DesfavorávelMetanálise ClínicaDor Câncer Efeitos Adversos da Cannabis CBD Farmacêutico Canabinol (CBN)+11
2022
Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals
FavorávelMetanáliseDor Dependência — Cannabis Dor — Crônica THC Farmacêutico CBD Farmacêutico+9
2022
What Do We Know About Medical Cannabis in Neurological Disorders and What Are the Next Steps?
FavorávelMetanáliseInflamação Estresse Oxidativo Doenças Neurodegenerativas Endocanabinoide (não especificado)Canabinoide Sintético (não especificado)+5
2022
Why Do Marijuana and Synthetic Cannabimimetics Induce Acute Myocardial Infarction in Healthy Young People?
DesfavorávelMetanáliseEfeitos Adversos da Cannabis Doenças Cardiovasculares (DCV)Infarto Anandamida (AEA)Tetraidrocanabinol (THC)+16
2021
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma
FavorávelEnsaio Clínico Duplo-CegoCâncer Câncer — Cérebro
2021
A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single-dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers
FavorávelEnsaio Clínico
2021
Cannabinoid interventions for improving cachexia outcomes in cancer: a systematic review and meta‐analysis
InconclusivoMetanáliseCâncer Caquexia THC Farmacêutico
2021
Cannabinoids for the treatment of refractory neuropathic pruritus in amyotrophic lateral sclerosis: A case report
FavorávelMetanáliseDoenças de Pele Esclerose Lateral Amiotrófica (ELA)Prurido
2021
Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials
InconclusivoMetanálise ClínicaDor Dor — Crônica Dor — Aguda THC Farmacêutico+6
2021
Cannabis Use and Car Crashes: A Review
DesfavorávelMetanáliseEfeitos Adversos da Cannabis
2021
Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome
FavorávelMetanáliseTiques e Síndrome de Tourette
2021
Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses
FavorávelMetanáliseEsclerose Múltipla
2021
Cost-Effectiveness of Medicinal Cannabis for Management of Refractory Symptoms Associated With Chronic Conditions: A Systematic Review of Economic Evaluations
FavorávelMetanáliseDor Dor — Crônica Epilepsia THC Farmacêutico CBD Farmacêutico+7
2021
Delivering therapeutic cannabinoids via skin: Current state and future perspectives
FavorávelMetanáliseTHC Farmacêutico CBD Farmacêutico
2021
Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity
FavorávelMetanáliseEsclerose Múltipla
2021
Effectiveness, safety and tolerability of nabiximols oromucosal spray versus typical oral long-acting opioid analgesics in patients with severe neuropathic back pain: analysis of 6-month real-world data from the German Pain e-Registry
FavorávelMetanáliseDor Dor — Crônica Dor — Neuropatia Periférica
2021
Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis
FavorávelMetanáliseEfeitos Adversos da Cannabis Epilepsia Epilepsia — Síndrome de Dravet THC Farmacêutico CBD Farmacêutico+2
2021
Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysis
FavorávelMetanálise ClínicaDor Dor — Crônica THC Farmacêutico Canabidivarina (CBDV)
2021
Efficacy of Δ9 -Tetrahydrocannabinol (THC) Alone or in Combination With a 1:1 Ratio of Cannabidiol (CBD) in Reversing the Spatial Learning Deficits in Old Mice
DesfavorávelEstudo em AnimaisDisfunção Cognitiva
2021
Evaluation of THC-Related Neuropsychiatric Symptoms Among Adults Aged 50 Years and Older: A Systematic Review and Metaregression Analysis
DesfavorávelMetanálise ClínicaEfeitos Adversos da Cannabis THC Farmacêutico
2021
Functional Connectivity Derived From Electroencephalogram in Pharmacoresistant Epileptic Encephalopathy Using Cannabidiol as Adjunctive Antiepileptic Therapy
FavorávelEnsaio ClínicoEpilepsia
2021
Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: a systematic review
FavorávelMetanáliseDisfunção Cognitiva Doenças Neurodegenerativas Insônia e Distúrbios do Sono THC Farmacêutico CBD Farmacêutico+5
2021
Nabiximols and botulinum toxin injections for patients with multiple sclerosis: efficacy on spasticity and spasms in a single-centre experience
FavorávelMetanáliseEsclerose Múltipla
2021
Nabiximols in Chronic Neuropathic Pain: A Meta-Analysis of Randomized Placebo-Controlled Trials
FavorávelMetanálise ClínicaDor Dor — Crônica
2021
Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions
DesfavorávelMetanáliseDor Dependência Química Efeitos Adversos da Cannabis 2-Araquidonoilglicerol (2-AG)Canabinoide Sintético (não especificado)+24
2021
Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders
FavorávelMetanáliseDependência — Cannabis Disfunção Cognitiva Psicose Anandamida (AEA)2-Araquidonoilglicerol (2-AG)+9
2021
Safety and efficacy of low-dose medical cannabis oils in multiple sclerosis
FavorávelEnsaio ClínicoEsclerose Múltipla THC Farmacêutico CBD Farmacêutico
2021
Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years" accumulated evidence from clinical trials
FavorávelMetanálise ClínicaDor Dor — Crônica Doenças Neurodegenerativas+6
2021
Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports
FavorávelMetanáliseDor Dor — Crônica Doenças Neurodegenerativas+2
2021
Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience
FavorávelMetanáliseEsclerose Múltipla
2021
Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity
FavorávelEnsaio ClínicoEsclerose Múltipla
2021
State of the science: cannabis and cannabinoids in palliative medicine-the potential
InconclusivoMetanáliseCuidados Paliativos
2021
Tetrahydrocannabinol and cannabidiol as an oromucosal spray in a 1:1 ratio: a therapeutic option for patients with central post-stroke pain syndrome?
FavorávelMetanáliseDor Dor — Crônica AVC+1
2021
The Utility of Delta-9-Tetrahydrocannibinol Therapy in a Multiple Sclerosis Patient with a Neoplastic Brain Lesion
FavorávelMetanáliseEsclerose Múltipla
2021
Tic Reduction in Adult Onset Gilles De La Tourette Syndrome Using as Required Nabiximols Spray
FavorávelMetanáliseTiques e Síndrome de Tourette
2021
Treatment with Delta-9-tetrahydrocannabinol/cannabidiol in Multiple Sclerosis: Influence on the Autonomy Profile according to the International Classification of Functioning, Disability and Health
FavorávelMetanáliseEsclerose Múltipla
2020
A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain
FavorávelMetanáliseDor Dor — Crônica
2020
Adherence to Consolidated Standards of Reporting Trials (CONSORT) Guidelines for Reporting Safety Outcomes in Trials of Medical Cannabis and Cannabis-based Medicines for Chronic Noncancer Pain: A Systematic Review
DesfavorávelMetanálise ClínicaDor Canabinoide Sintético (não especificado)THC Farmacêutico
2020
Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies
FavorávelMetanáliseAutismo THC Farmacêutico CBD Farmacêutico
2020
Cannabinoids in multiple sclerosis: A neurophysiological analysis
FavorávelEnsaio ClínicoEsclerose Múltipla
2020
Cannabis and multiple sclerosis
FavorávelMetanáliseEsclerose Múltipla
2020
Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial
FavorávelEnsaio Clínico Duplo-CegoDependência Química Efeitos Adversos da Cannabis Dependência — Cannabis THC Farmacêutico+1
2020
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis
FavorávelMetanáliseEsclerose Múltipla
2020
Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study
FavorávelEnsaio ClínicoEsclerose Múltipla
2020
Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial
InconclusivoEnsaio Clínico Duplo-CegoParalisia Cerebral
2020
It Is Our Turn to Get Cannabis High: Put Cannabinoids in Food and Health Baskets
FavorávelMetanáliseTHC Farmacêutico Canabigerol (CBG)+4
2020
Long-term assessment of the cognitive effects of nabiximols in patients with multiple sclerosis: A pilot study
FavorávelEnsaio ClínicoEsclerose Múltipla
2020
Natural cannabinoids suppress the cytokine storm in sepsis-like in vitro model
FavorávelEstudo LaboratorialSepse
2020
Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial
FavorávelEnsaio Clínico Duplo-CegoCâncer Náusea e Vômito Náusea e Vômito por Quimioterapia
2020
Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders
FavorávelEstudo em AnimaisAplicações Veterinárias
2020
Pharmacotherapeutic Considerations for Use of Cannabinoids to Relieve Symptoms of Nausea and Vomiting Induced by Chemotherapy
FavorávelMetanálise ClínicaNáusea e Vômito Síndrome da Hiperêmese Canabinoide Tetraidrocanabinol (THC)THC Farmacêutico+2
2020
Roles of Cannabinoids in Melanoma: Evidence from In Vivo Studies
FavorávelMetanáliseCâncer Câncer — Melanoma THC Farmacêutico Canabinoides Sintéticos WIN-x+1
2020
Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial
FavorávelEnsaio Clínico Duplo-CegoDor Esclerose Múltipla Dor — Oncológica
2020
The Broad Concept of "Spasticity-Plus Syndrome" in Multiple Sclerosis: A Possible New Concept in the Management of Multiple Sclerosis Symptoms
FavorávelMetanáliseEsclerose Múltipla
2020
The effects of cannabis, cannabinoids, and their administration routes on pain control efficacy and safety: A systematic review and network meta-analysis
FavorávelMetanálise ClínicaDor Dor — Oncológica THC Farmacêutico
2020
The Role of Cannabidiol (CBD) in Chronic Pain Management: An Assessment of Current Evidence
FavorávelMetanáliseDor Dor — Crônica
2020
Use of cannabidiol (CBD) for the treatment of chronic pain
FavorávelMetanáliseDor Dor — Crônica
2019
A Multicriteria Decision Analysis Comparing Pharmacotherapy for Chronic Neuropathic Pain, Including Cannabinoids and Cannabis-Based Medical Products
FavorávelMetanáliseDor Dor — Crônica THC Farmacêutico CBD Farmacêutico
2019
A Review of Cannabis in Chronic Kidney Disease Symptom Management
FavorávelMetanáliseDoença Renal Crônica
2019
A role for cannabinoids in the treatment of myotonia? Report of compassionate use in a small cohort of patients
FavorávelEnsaio ClínicoDistrofia Muscular e Distúrbios Miotônicos
2019
Application device for THC:CBD oromucosal spray in the management of resistant spasticity: pre-production testing
FavorávelEnsaio ClínicoEsclerose Múltipla
2019
Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD
FavorávelMetanálise ClínicaDependência Química Dependência — Estimulantes TDA e TDAH
2019
Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System
FavorávelMetanáliseCâncer Doenças de Pele Câncer — Melanoma Anandamida (AEA)2-Araquidonoilglicerol (2-AG)+15
2019
Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome
FavorávelEstudo em AnimaisEsclerose Múltipla Desequilíbrio do Microbioma Encefalite e Mielite Microbioma
2019
Combination of Cannabinoids, Δ9- Tetrahydrocannabinol and Cannabidiol, Ameliorates Experimental Multiple Sclerosis by Suppressing Neuroinflammation Through Regulation of miRNA-Mediated Signaling Pathways
FavorávelEstudo em AnimaisEsclerose Múltipla
2019
Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases
FavorávelMetanáliseEpidermólise Bolhosa
2019
Detection of Δ9 THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point-of-collection testing devices
DesfavorávelEstudo LaboratorialTHC Farmacêutico
2019
Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry
FavorávelMetanáliseDor Dor — Crônica
2019
Efficacy and safety of cannabidiol followed by an open label add-on of tetrahydrocannabinol for the treatment of chronic pain in patients with rheumatoid arthritis or ankylosing spondylitis: protocol for a multicenter, randomized, placebo-controlled study
InconclusivoEnsaio Clínico Duplo-CegoDor Dor — Crônica Artrite+1
2019
Future Aspects for Cannabinoids in Breast Cancer Therapy
FavorávelMetanáliseCâncer Câncer — Mama Anandamida (AEA)2-Araquidonoilglicerol (2-AG)+11
2019
Medical Cannabis Use in Palliative Care: Review of Clinical Effectiveness and Guidelines – An Update
FavorávelMetanáliseCuidados Paliativos Tetraidrocanabinol (THC)THC Farmacêutico
2019
Nabiximols for the Treatment of Cannabis Dependence: A Randomized Clinical Trial
FavorávelEnsaio Clínico Duplo-CegoDependência Química Dependência — Cannabis
2019
Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from randomized clinical trials
FavorávelMetanáliseEsclerose Múltipla Tetraidrocanabinol (THC)
2019
Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
FavorávelEnsaio Clínico Duplo-CegoDoenças Neurodegenerativas Esclerose Lateral Amiotrófica (ELA)
2019
The Endocannabinoid System: A New Treatment Target for Obsessive Compulsive Disorder?
FavorávelMetanáliseTOC THC Farmacêutico CBD Farmacêutico
2019
The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray)
FavorávelEnsaio ClínicoEsclerose Múltipla
2019
The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review
FavorávelMetanáliseDependência Química Dependência — Cannabis Psicose+1
2018
[EFFECTS OF CANNABIS EXTRACT PREMEDICATION ON ANESTHETIC DEPTH]
DesfavorávelEnsaio Clínico Duplo-CegoDor Tetraidrocanabinol (THC)
2018
A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders
FavorávelMetanáliseAnsiedade Disfunção Cognitiva Psicose THC Farmacêutico+6
2018
A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms
FavorávelMetanálise ClínicaDependência Química Dependência — Cannabis Ansiedade Tetraidrocanabinol (THC)Canabinoide Sintético (não especificado)+4
2018
Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?
FavorávelMetanáliseEsclerose Múltipla Doença de Parkinson Doença de Huntington Tetraidrocanabinol (THC)
2018
Cannabinoids for Treatment of Dystonia in Huntington's Disease.
FavorávelEnsaio ClínicoDoença de Huntington Distonia Coreia Tetraidrocanabinol (THC)THC Farmacêutico
2018
Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer
FavorávelMetanáliseDor Câncer Inflamação Anandamida (AEA)2-Araquidonoilglicerol (2-AG)+5
2018
Cannabis‐based medicines for chronic neuropathic pain in adults
FavorávelMetanáliseDor Dor — Crônica THC Farmacêutico
2018
Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis.
FavorávelEnsaio ClínicoEsclerose Múltipla
2018
Delta-9-tetrahydrocannabinol-cannabidiol in the treatment of spasticity in chronic spinal cord injury: a clinical experience.
FavorávelEnsaio ClínicoLesões da Medula Espinhal Tetraidrocanabinol (THC)
2018
Medical use of cannabis: Italian and European legislation.
FavorávelMetanáliseDor Ansiedade Esclerose Múltipla THC Farmacêutico Outros Compostos Relacionados+9
2018
Nabiximols Combined With Motivational Enhancement/cognitive Behavioral Therapy For The Treatment Of Cannabis Dependence: A Pilot Randomized Clinical Trial
FavorávelEnsaio Clínico Duplo-CegoDependência Química Dependência — Cannabis Tetraidrocanabinol (THC)
2018
Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma
FavorávelEstudo em AnimaisCâncer Câncer — Cérebro
2018
Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study
FavorávelEnsaio ClínicoEfeitos Adversos da Cannabis Esclerose Múltipla Tetraidrocanabinol (THC)
2018
Pharmacotherapeutic considerations for use of cannabinoids to relieve pain in patients with malignant diseases
FavorávelMetanáliseDor Dor — Crônica Dor — Neuropatia Periférica Tetraidrocanabinol (THC)THC Farmacêutico+3
2018
Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol
FavorávelMetanáliseCâncer Esclerose Múltipla Câncer — Mama CBD Farmacêutico+5
2018
Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain.
FavorávelEnsaio Clínico Duplo-CegoDor Dor — Oncológica Tetraidrocanabinol (THC)
2018
Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation
FavorávelMetanálise ClínicaEsclerose Múltipla Tetraidrocanabinol (THC)
2018
Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial
FavorávelEnsaio Clínico Duplo-CegoEsclerose Múltipla Tetraidrocanabinol (THC)
2018
Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis
FavorávelMetanáliseEsclerose Múltipla
2018
Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship
FavorávelEnsaio ClínicoEsclerose Múltipla Tetraidrocanabinol (THC)
2018
THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study
FavorávelEnsaio ClínicoEsclerose Múltipla Tetraidrocanabinol (THC)
2018
The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews.
FavorávelMetanáliseEsclerose Múltipla Tetraidrocanabinol (THC)THC Farmacêutico
2018
Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis.
FavorávelMetanáliseEsclerose Múltipla Anandamida (AEA)Tetraidrocanabinol (THC)+9
2017
A selective review of medical cannabis in cancer pain management.
FavorávelMetanáliseDor Dor — Oncológica Tetraidrocanabinol (THC)
2017
Big conductance calcium-activated potassium channel openers control spasticity without sedation
FavorávelEstudo em AnimaisEsclerose Múltipla Encefalite e Mielite Anandamida (AEA)Endocanabinoide (não especificado)
2017
Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?
FavorávelMetanáliseDII — Doença Inflamatória Intestinal Síndrome do Intestino Irritável DII — Doença de Crohn Anandamida (AEA)Endocanabinoide (não especificado)+5
2017
Cannabinoids In Attention-deficit/hyperactivity Disorder: A Randomised-controlled Trial
FavorávelEnsaio Clínico Duplo-CegoTDA e TDAH Tetraidrocanabinol (THC)
2017
Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity
FavorávelMetanáliseEsclerose Múltipla
2017
iperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration
FavorávelEnsaio ClínicoAnsiedade Estresse Oxidativo Esclerose Múltipla
2017
Opioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis.
FavorávelMetanáliseDor Dependência Química Dependência — Opioides Tetraidrocanabinol (THC)THC Farmacêutico+8
2017
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study)
FavorávelMetanáliseEsclerose Múltipla
2017
Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies
InconclusivoMetanálise ClínicaDor Dor — Oncológica Tetraidrocanabinol (THC)
2017
Sativex® effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients
FavorávelEnsaio ClínicoDor Inflamação Dor — Crônica+2
2017
Selective Cannabinoids for Chronic Neuropathic Pain: A Systematic Review and Meta-analysis
FavorávelMetanálise ClínicaDor Dor — Crônica Dor — Neuropatia Periférica THC Farmacêutico+4
2017
Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology
FavorávelEnsaio ClínicoInflamação Ansiedade Depressão+4
2017
Targeting Cannabinoid Signaling in the Immune System: “High”-ly Exciting Questions, Possibilities, and Challenges.
FavorávelMetanáliseEsclerose Múltipla Artrite HIV/AIDS Anandamida (AEA)Tetraidrocanabinol (THC)+20
2017
Toll-like receptor signalling as a cannabinoid target in Multiple Sclerosis.
FavorávelMetanáliseEsclerose Múltipla Tetraidrocanabinol (THC)
2016
A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.
FavorávelMetanáliseEsclerose Múltipla
2016
A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease
FavorávelEnsaio Clínico Duplo-CegoDisfunção Cognitiva Doenças Neurodegenerativas Transtornos de Comportamento+1
2016
Cannabinoids for Symptom Management and Cancer Therapy: The Evidence.
FavorávelMetanáliseNáusea e Vômito Endocanabinoide (não especificado)Canabinoide Sintético (não especificado)+1
2016
Cannabinoids, Inflammation, and Fibrosis
FavorávelMetanáliseInflamação Doenças Cardiovasculares (DCV)Fibrose THC Farmacêutico Canabinol (CBN)+5
2016
Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes
InconclusivoMetanáliseSíndrome do Intestino Irritável Enxaqueca Fibromialgia Anandamida (AEA)2-Araquidonoilglicerol (2-AG)+3
2016
Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings
FavorávelEnsaio Clínico Duplo-CegoDependência Química Efeitos Adversos da Cannabis Dependência — Cannabis+2
2016
Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
FavorávelMetanáliseEsclerose Múltipla Tetraidrocanabinol (THC)
2016
Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.
FavorávelMetanáliseEsclerose Múltipla Tetraidrocanabinol (THC)
2016
Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: A systematic review of randomized controlled studies.
FavorávelMetanálise ClínicaDor Dor — Crônica Dor — Neuropatia Periférica Canabinoide Sintético (não especificado)THC Farmacêutico
2016
Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting--a systematic review of systematic reviews.
FavorávelMetanáliseNáusea e Vômito Náusea e Vômito por Quimioterapia THC Farmacêutico
2016
Endocannabinoid System: A Multi-Facet Therapeutic Target.
FavorávelMetanáliseDoenças Cardiovasculares (DCV)Epilepsia Esclerose Múltipla Tetraidrocanabinol (THC)Canabinoide Sintético (não especificado)+11
2016
Endocannabinoids as Guardians of Metastasis
FavorávelMetanáliseCâncer Câncer — Metastático
2016
Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis
FavorávelEnsaio ClínicoDor Inflamação Dor — Crônica+5
2016
Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity
FavorávelEnsaio ClínicoInsônia e Distúrbios do Sono Esclerose Múltipla
2016
Integrating cannabis into clinical cancer care
FavorávelMetanáliseDor Câncer Náusea e Vômito+11
2016
Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers
FavorávelEnsaio ClínicoDor Dependência Química Câncer Anandamida (AEA)Hidrolase de Amidas de Ácidos Graxos (FAAH)+13
2016
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper
FavorávelMetanáliseEsclerose Múltipla
2016
Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence: A Case Series
FavorávelEnsaio ClínicoDependência Química Efeitos Adversos da Cannabis Dependência — Cannabis Medicina Mente-Corpo+1
2016
Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice
FavorávelEnsaio ClínicoEsclerose Múltipla Qualidade de Vida
2016
THC:CBD in Daily Practice: Available Data from UK, Germany and Spain.
FavorávelMetanáliseEsclerose Múltipla
2016
The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.
FavorávelEnsaio ClínicoEsclerose Múltipla Tetraidrocanabinol (THC)
2016
Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex®
FavorávelEnsaio ClínicoDoenças Neurodegenerativas Esclerose Múltipla
2015
[Assessment of the effectiveness and safety of Sativex® in compassionate use]
FavorávelEnsaio ClínicoDor Dor — Crônica Dor — Neuropatia Periférica
2015
Cannabinoid CB1 Receptor Agonists Do Not Decrease, but may Increase Acoustic Trauma-Induced Tinnitus in Rats
DesfavorávelEstudo em AnimaisZumbido
2015
Cannabinoids in experimental stroke: a systematic review and meta-analysis
FavorávelEstudo em AnimaisAVC Anandamida (AEA)Tetraidrocanabinol (THC)+6
2015
Is There a Place for Off-Label Pharmacotherapy in Cannabis Use Disorder? A Review on Efficacy and Safety
InconclusivoMetanálise ClínicaDependência Química Efeitos Adversos da Cannabis Dependência — Cannabis THC Farmacêutico
2015
Possible opioid-saving effect of cannabis-based medicine using individual-based data from the Norwegian Prescription Database
DesfavorávelMetanáliseDependência Química Dependência — Opioides
2015
Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis
FavorávelEnsaio Clínico Duplo-CegoEsclerose Múltipla
2014
A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment
FavorávelEnsaio Clínico Duplo-CegoDor Insônia e Distúrbios do Sono Dor — Neuropatia Periférica Tetraidrocanabinol (THC)
2014
A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain
FavorávelEnsaio ClínicoDor Dor — Neuropatia Periférica Dor — Neuropatia Diabética Tetraidrocanabinol (THC)
2014
Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
FavorávelMetanáliseInflamação Dependência — Cannabis Ansiedade Anandamida (AEA)2-Araquidonoilglicerol (2-AG)+17
2014
Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial
FavorávelEnsaio Clínico Duplo-CegoDependência Química Efeitos Adversos da Cannabis Dependência — Cannabis
2014
Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes
FavorávelMetanálise ClínicaEsclerose Múltipla Tetraidrocanabinol (THC)
2014
Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology
FavorávelMetanálise ClínicaDor Epilepsia Esclerose Múltipla THC Farmacêutico CBD Farmacêutico+5
2014
The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC–MS/MS
DesfavorávelEnsaio Clínico Duplo-CegoEsclerose Múltipla Efeitos Adversos do MDMA Canabinol (CBN)
2013
A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain
FavorávelEnsaio ClínicoDor Câncer Ansiedade+6
2013
Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report
FavorávelMetanálise
2012
A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis
InconclusivoEnsaio Clínico Duplo-CegoDor Dor — Crônica Esclerose Múltipla+2
2012
An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics
FavorávelEnsaio ClínicoDor Câncer Ansiedade Endocanabinoide (não especificado)THC Farmacêutico+10
2012
Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?
FavorávelEnsaio ClínicoDor Efeitos Adversos da Cannabis Dependência — Cannabis Canabinol (CBN)+10
2012
Cannabinoids: novel medicines for the treatment of Huntington's disease
FavorávelMetanáliseDoença de Huntington Distonia Coreia
2012
Cannabis—A Valuable Drug That Deserves Better Treatment
InconclusivoMetanáliseInflamação Ansiedade Psicose Endocanabinoide (não especificado)Canabinoide Sintético (não especificado)+6
2012
Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial
FavorávelEnsaio Clínico Duplo-CegoDor Câncer Dor — Crônica+3
2012
Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis
FavorávelEnsaio ClínicoPsicose Esclerose Múltipla
2012
Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities.
FavorávelMetanáliseDor Esclerose Múltipla Náusea e Vômito Tetraidrocanabinol (THC)THC Farmacêutico+4
2011
A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols)
FavorávelEnsaio ClínicoDor Ansiedade Dor — Crônica Anandamida (AEA)Endocanabinoide (não especificado)+8
2011
A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use
DesfavorávelEnsaio Clínico Duplo-CegoEfeitos Adversos da Cannabis Dependência — Cannabis Disfunção Cognitiva THC Farmacêutico+1
2011
Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials.
FavorávelMetanálise ClínicaDor Dor — Crônica Dor — Neuropatia Periférica THC Farmacêutico+3
2011
Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.
FavorávelEstudo em AnimaisDoença de Huntington Tetraidrocanabinol (THC)Canabinoides Sintéticos AM-x+1
2011
Subjective and physiological effects after controlled Sativex and oral THC administration
InconclusivoEnsaio ClínicoAnsiedade Psicose Tetraidrocanabinol (THC)THC Farmacêutico
2010
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
FavorávelEnsaio Clínico Duplo-CegoEsclerose Múltipla
2010
Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration
DesfavorávelEnsaio Clínico Duplo-CegoTHC Farmacêutico
2010
Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting.
FavorávelEnsaio Clínico Duplo-CegoNáusea e Vômito Náusea e Vômito por Quimioterapia
2010
Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis
InconclusivoEnsaio Clínico Duplo-CegoEsclerose Múltipla
2010
Randomized Placebo-Controlled Double-Blind Clinical Trial of Cannabis-Based Medicinal Product (Sativex) in Painful Diabetic Neuropathy
InconclusivoEnsaio Clínico Duplo-CegoDor Depressão Dor — Neuropatia Diabética Tetraidrocanabinol (THC)
2009
Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis.
FavorávelEnsaio Clínico Duplo-CegoDor Esclerose Múltipla Tetraidrocanabinol (THC)
2009
Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis
DesfavorávelEnsaio ClínicoEsclerose Múltipla
2009
Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study.
FavorávelEnsaio Clínico Duplo-CegoEsclerose Múltipla Tetraidrocanabinol (THC)
2008
Management of bone metastases
FavorávelMetanáliseDor Câncer Câncer — Mama+9
2007
Cannabinoids in health and disease
FavorávelMetanáliseDor Inflamação Dependência — Cannabis Anandamida (AEA)Tetraidrocanabinol (THC)+25
2007
Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine
FavorávelEnsaio ClínicoDor Insônia e Distúrbios do Sono Esclerose Múltipla+4
2007
Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial
FavorávelEnsaio ClínicoDor Esclerose Múltipla Dor — Síndrome da Dor Central Tetraidrocanabinol (THC)
2007
Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial
FavorávelEnsaio Clínico Duplo-CegoDor Dor — Neuropatia Periférica
2006
Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis
InconclusivoEnsaio ClínicoEsclerose Múltipla
2006
Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis
FavorávelEnsaio Clínico Duplo-CegoDor Inflamação Dor — Crônica Tetraidrocanabinol (THC)+3
2006
Sativex®: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
FavorávelMetanáliseDor Esclerose Múltipla Dor — Neuropatia Periférica Tetraidrocanabinol (THC)
2005
Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential.
FavorávelMetanáliseTranstorno Bipolar Anandamida (AEA)THC Farmacêutico
2005
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
FavorávelEnsaio Clínico Duplo-CegoDor Insônia e Distúrbios do Sono Esclerose Múltipla Tetraidrocanabinol (THC)+1
2005
Sativex for the management of multiple sclerosis symptoms.
FavorávelMetanáliseEsclerose Múltipla Tetraidrocanabinol (THC)
2004
Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial
FavorávelEnsaio Clínico Duplo-CegoDor Dor — Crônica Lesões do Plexo Braquial THC Farmacêutico
2003
Efficacy of two cannabis‐based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial
FavorávelEnsaio Clínico Duplo-CegoDor Dor — Aguda Dor — Síndrome da Dor Central Tetraidrocanabinol (THC)+1

Perguntas frequentes

Quantos estudos sobre thc:cbd farmacêutico estão indexados no acervo?

São 248 estudos, publicados entre 2003 e 2024. O acervo inteiro tem 7.640 registros.

Que tipos de estudo predominam?

Metanálise: 109 · Ensaio Clínico: 46 · Ensaio Clínico Duplo-Cego: 42 · Metanálise Clínica: 37 · Estudo em Animais: 11 · Estudo Laboratorial: 3. A classificação segue o desenho declarado na fonte.

O que significa a classificação de resultado?

É uma leitura automatizada da conclusão de cada estudo, em três direções — favorável, inconclusivo e desfavorável. Aqui são 199 favoráveis, 29 inconclusivos e 20 desfavoráveis. Serve para navegar o acervo, não para concluir nada clinicamente: a conclusão válida é a do artigo original.

Como citar esta página

ABNT

CANNABIS INDICA. THC:CBD Farmacêutico — estudos científicos sobre cannabis. 2026. Disponível em: https://cannabisindica.com.br/canabinoide/thc-cbd-farmaceutico/. Acesso em: 13 set. 2026.

APA

Cannabis Indica. (2026). THC:CBD Farmacêutico — estudos científicos sobre cannabis. https://cannabisindica.com.br/canabinoide/thc-cbd-farmaceutico/

Esta página é um índice de acesso. Ao usar um estudo como evidência, cite o artigo original — o link de cada registro leva à fonte.